Targeting metabolic functional proteins selectively and highly expressed in glioma cells, such as GLUT3 (Xu et al., 2015; Zheng et al., 2016), or using targeted metabolic drug delivery systems based on neutrophils (Osuka and Van Meir, 2017; Xue et al., 2017) or other immune cells accumulating in glioma tissues is also a good solution. Here, SLC2A3 is linked to glioma.